Search

Your search keyword '"Pantarotto, Jason"' showing total 164 results
Start Over Author "Pantarotto, Jason"
164 results on '"Pantarotto, Jason"'

1. Use of radiotherapy in patients with oesophageal, stomach, colon, rectal, liver, pancreatic, lung, and ovarian cancer: an International Cancer Benchmarking Partnership (ICBP) population-based study

Author

Bennett, Damien, Butler, John, Cameron, David A, Chew, Cindy, Crosby, Tom, Filsinger, Brooke, Finley, Christian J, Forster, Katharina, Fung, Sharon, Green, Bo, Gomez-Navas, Elba, Gutierrez, Eric, Han, Jihee, Harrison, Samantha, Lawler, Mark, Little, Alana L, Pantarotto, Jason R, Peacock, Stuart J, Ray-Coquard, Isabelle, Thomson, Catherine S, Warlow, Janet L, Whitfield, Emma, McPhail, Sean, Barclay, Matthew E, Swann, Ruth, Johnson, Shane A, Alvi, Riaz, Barisic, Andriana, Bucher, Oliver, Creighton, Nicola, Denny, Cheryl A, Dewar, Ron A, Donnelly, David W, Dowden, Jeff J, Downie, Laura, Finn, Norah, Gavin, Anna T, Habbous, Steven, Huws, Dyfed W, Kumar, S Eshwar, May, Leon, McClure, Carol A, Morrison, David S, Møller, Bjørn, Musto, Grace, Nilssen, Yngvar, Saint-Jacques, Nathalie, Sarker, Sabuj, Shack, Lorraine, Tian, Xiaoyi, Thomas, Robert JS, Wang, Haiyan, Woods, Ryan R, You, Hui, Zhang, Bin, and Lyratzopoulos, Georgios

Published
2024
Full Text
View/download PDF

3. Use of radiotherapy in patients with oesophageal, stomach, colon, rectal, liver, pancreatic, lung, and ovarian cancer: an International Cancer Benchmarking Partnership (ICBP) population-based study

Author

McPhail, Sean, primary, Barclay, Matthew E, additional, Swann, Ruth, additional, Johnson, Shane A, additional, Alvi, Riaz, additional, Barisic, Andriana, additional, Bucher, Oliver, additional, Creighton, Nicola, additional, Denny, Cheryl A, additional, Dewar, Ron A, additional, Donnelly, David W, additional, Dowden, Jeff J, additional, Downie, Laura, additional, Finn, Norah, additional, Gavin, Anna T, additional, Habbous, Steven, additional, Huws, Dyfed W, additional, Kumar, S Eshwar, additional, May, Leon, additional, McClure, Carol A, additional, Morrison, David S, additional, Møller, Bjørn, additional, Musto, Grace, additional, Nilssen, Yngvar, additional, Saint-Jacques, Nathalie, additional, Sarker, Sabuj, additional, Shack, Lorraine, additional, Tian, Xiaoyi, additional, Thomas, Robert JS, additional, Wang, Haiyan, additional, Woods, Ryan R, additional, You, Hui, additional, Zhang, Bin, additional, Lyratzopoulos, Georgios, additional, Bennett, Damien, additional, Butler, John, additional, Cameron, David A, additional, Chew, Cindy, additional, Crosby, Tom, additional, Filsinger, Brooke, additional, Finley, Christian J, additional, Forster, Katharina, additional, Fung, Sharon, additional, Green, Bo, additional, Gomez-Navas, Elba, additional, Gutierrez, Eric, additional, Han, Jihee, additional, Harrison, Samantha, additional, Lawler, Mark, additional, Little, Alana L, additional, Pantarotto, Jason R, additional, Peacock, Stuart J, additional, Ray-Coquard, Isabelle, additional, Thomson, Catherine S, additional, Warlow, Janet L, additional, and Whitfield, Emma, additional

Published
2024
Full Text
View/download PDF

4. Safety and Efficacy of a Five-Fraction Stereotactic Body Radiotherapy Schedule for Centrally Located Non-Small-Cell Lung Cancer: NRG Oncology/RTOG 0813 Trial.

Author

Bezjak, Andrea, Paulus, Rebecca, Gaspar, Laurie E, Timmerman, Robert D, Straube, William L, Ryan, William F, Garces, Yolanda I, Pu, Anthony T, Singh, Anurag K, Videtic, Gregory M, McGarry, Ronald C, Iyengar, Puneeth, Pantarotto, Jason R, Urbanic, James J, Sun, Alexander Y, Daly, Megan E, Grills, Inga S, Sperduto, Paul, Normolle, Daniel P, Bradley, Jeffrey D, and Choy, Hak

Subjects
Biomedical and Clinical Sciences, Clinical Sciences, Oncology and Carcinogenesis, Lung, Clinical Research, Lung Cancer, Clinical Trials and Supportive Activities, Cancer, Evaluation of treatments and therapeutic interventions, 6.5 Radiotherapy and other non-invasive therapies, Aged, Aged, 80 and over, Carcinoma, Non-Small-Cell Lung, Dose Fractionation, Radiation, Dose-Response Relationship, Radiation, Female, Humans, Lung Neoplasms, Male, Middle Aged, Radiosurgery, Treatment Outcome, Oncology & Carcinogenesis, Oncology and carcinogenesis
Abstract

PurposePatients with centrally located early-stage non-small-cell lung cancer (NSCLC) are at a higher risk of toxicity from high-dose ablative radiotherapy. NRG Oncology/RTOG 0813 was a phase I/II study designed to determine the maximum tolerated dose (MTD), efficacy, and toxicity of stereotactic body radiotherapy (SBRT) for centrally located NSCLC.Materials and methodsMedically inoperable patients with biopsy-proven, positron emission tomography-staged T1 to 2 (≤ 5 cm) N0M0 centrally located NSCLC were accrued into a dose-escalating, five-fraction SBRT schedule that ranged from 10 to 12 Gy/fraction (fx) delivered over 1.5 to 2 weeks. Dose-limiting toxicity (DLT) was defined as any treatment-related grade 3 or worse predefined toxicity that occurred within the first year. MTD was defined as the SBRT dose at which the probability of DLT was closest to 20% without exceeding it.ResultsOne hundred twenty patients were accrued between February 2009 and September 2013. Patients were elderly, there were slightly more females, and the majority had a performance status of 0 to 1. Most cancers were T1 (65%) and squamous cell (45%). Organs closest to planning target volume/most at risk were the main bronchus and large vessels. Median follow-up was 37.9 months. Five patients experienced DLTs; MTD was 12.0 Gy/fx, which had a probability of a DLT of 7.2% (95% CI, 2.8% to 14.5%). Two-year rates for the 71 evaluable patients in the 11.5 and 12.0 Gy/fx cohorts were local control, 89.4% (90% CI, 81.6% to 97.4%) and 87.9% (90% CI, 78.8% to 97.0%); overall survival, 67.9% (95% CI, 50.4% to 80.3%) and 72.7% (95% CI, 54.1% to 84.8%); and progression-free survival, 52.2% (95% CI, 35.3% to 66.6%) and 54.5% (95% CI, 36.3% to 69.6%), respectively.ConclusionThe MTD for this study was 12.0 Gy/fx; it was associated with 7.2% DLTs and high rates of tumor control. Outcomes in this medically inoperable group of mostly elderly patients with comorbidities were comparable with that of patients with peripheral early-stage tumors.

Published
2019

14. Directly Improving the Quality of Radiation Treatment Through Peer Review: A Cross-sectional Analysis of Cancer Centers Across a Provincial Cancer Program

Author

Czarnota, Gregory, El-Mallah, Medhat, Falkson, Conrad, Liu, Fei-Fei, Gulavita, Sunil, McMillan, William, Pantarotto, Jason, Rachakonda, Ramana, Read, Nancy, Schneider, Ken, Shehata, Sarwat, Stevens, Christiaan, Tsao, Jonathan, Waldron, John, Wells, Woodrow, Wright, Jim, Warde, Padraig, Sharpe, Michael, Lockhart, Elizabeth, Brundage, Michael, Hart, Margaret, Caissie, Amanda, Hollenhorst, Helmut, Wilson, Lianne, Parliament, Matthew, Milosevic, Michael, Halperin, Ross, Foxcroft, Sophie, Ebacher, Annie, McGowan, Thomas, Rouette, Julie, Gutierrez, Eric, O'Donnell, Jennifer, Reddeman, Lindsay, Mitera, Gunita, and Brundage, Michael D.

Published
2017
Full Text
View/download PDF

15. A Clinical Consensus Approach to Developing a New Funding Model for Radiation Services in Ontario

Author

Apostolovski, Suzanna, primary, McCallum, Farzana, additional, Simniceanu, Carina, additional, Kraus, Julie, additional, Gutierrez, Eric, additional, Liszewski, Brian, additional, Esselink, Emma, additional, Bissonnette, Jean-Pierre, additional, Hart, Margaret, additional, Brundage, Michael, additional, Warde, Padraig, additional, and Pantarotto, Jason, additional

Published
2023
Full Text
View/download PDF

16. Pan-Canadian consensus recommendations for proton beam therapy access in Canada

Author

Mitera, Gunita, primary, Tsang, Derek, additional, McCurdy, Boyd, additional, Goddard, Karen, additional, Ebacher, Annie, additional, Craig, Tim, additional, Greenland, Jonathan, additional, Kentish, Staci, additional, Koul, Rashmi, additional, Logie, Natalie, additional, Morneau, Mélanie, additional, Morrison, Andra, additional, Pan, Larry, additional, Pantarotto, Jason, additional, Foxcroft, Sophie, additional, Sussman, Jonathan, additional, Thompson, Robert, additional, Tyldesley, Scott, additional, Wright, Philip, additional, Hicks, Sarah, additional, Brown, Erika, additional, and Patel, Samir, additional

Published
2022
Full Text
View/download PDF

17. Ablative vs. Non-Ablative Radiotherapy in Palliating Locally Advanced Pancreatic Cancer: A Single Institution Experience and a Systematic Review of the Literature.

Author

Kamel, Randa, Dennis, Kristopher, Doody, Janice, and Pantarotto, Jason

Subjects
PANCREATIC tumors, DISEASE progression, MEDICAL databases, MEDICAL information storage & retrieval systems, CONFIDENCE intervals, SYSTEMATIC reviews, LIFE expectancy, RETROSPECTIVE studies, ACQUISITION of data, DOSE-response relationship (Radiation), COMPARATIVE studies, MEDICAL records, DESCRIPTIVE statistics, QUALITY of life, LITERATURE reviews, MEDLINE, RADIOSURGERY, ABLATION techniques, PALLIATIVE treatment, LONGITUDINAL method, OVERALL survival
Abstract

Simple Summary: The very poor prognosis and the absence of radical treatment options in cases of unresectable "locally advanced pancreatic cancer (LAPC)" focus its management on palliation. An "overall survival (OS)" benefit has been shown with new systemic therapy agents; however, not all patients are good candidates for systemic treatments at diagnosis, and LAPC is often associated with a high symptom burden that greatly impacts patients' quality of life. Studying dose optimization of radiation as an option for local progression cessation is therefore necessary. Research in this setting as opposed to other treatment sites is under-represented in the literature and the guidelines are based on very scarce data. We aim to present the outcomes of "stereotactic body radiotherapy (SBRT)" (ablative radiotherapy) vs. non-ablative radiotherapy through our patient population and the available data in the literature. We studied the dose–local control (LC) relationship in ablative vs. non-ablative radiotherapy in a non-radical treatment setting of "locally advanced pancreatic cancer (LAPC)" by comparing our patients (n = 89) treated with SBRT on the CyberKnife unit vs. conventional radiation between January 2005 and January 2021, and by reviewing the literature. A systematic search was performed leveraging Medline for references on SBRT use in pancreatic cancer without date terms or language restrictions. A total of 3702 references were identified and the search was then repeated in Embase and the Cochrane database. Ultimately, 12 studies were eligible for inclusion, which either compared SBRT to conventional radiation, or SBRT use in dose escalation for primary LAPC in a non-neoadjuvant setting. Our cohort's median overall survival was 152 days (CI 95%, 118–185); including 371 days (CI 95%, 230–511) vs. 126 days (CI 95%, 90–161) favoring SBRT, p = 0.004. The median time to local progression was 170 days (48–923) for SBRT vs. 107 days (27–489) for the non-ablative group. In our SBRT patients, no local progressions were seen with BED10 > 60 Gy. Even when palliating LAPC, SBRT should be considered as an alternative to conventional radiation, especially in patients with a low disease burden. BED10 ≥ 60–70 Gy offers better local control without increasing toxicity rates. Less local progression may provide a better quality of life to those patients who already have a short life expectancy. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

20. Cancer Clinic Redesign: Opportunities for Resource Optimization

Author

Fung-Kee-Fung, Michael, primary, Ozer, Rachel S., additional, Davies, Bill, additional, Pick, Stephanie, additional, Duke, Kate, additional, Stewart, David J., additional, Reaume, M. Neil, additional, Ward, Marcus, additional, Balchin, Katelyn, additional, MacRae, Robert M., additional, Nelson, Shannon, additional, Renaud, Julie, additional, Garvin, Dennis, additional, Madore, Suzanne, additional, and Pantarotto, Jason R., additional

Published
2022
Full Text
View/download PDF

24. Assessment of function and quality of life in a phase II multi-institutional clinical trial of fractionated simultaneous in-field boost radiotherapy for patients with 1–3 metastases

Author

Bauman, Glenn, Yartsev, Slav, Roberge, David, MacRae, Robert, Roa, Wilson, Panet-Raymond, Valerie, Masucci, Laura, Yaremko, Brian, D’Souza, David, Palma, David, Sexton, Tracy, Yu, Edward, Pantarotto, Jason R., Ahmad, Belal, Fisher, Barbara, Dar, A. Rashid, Lambert, Carole, Pond, Gregory, Stitt, Larry, Tay, Keng Yeow, and Rodrigues, George

Published
2016
Full Text
View/download PDF

25. Cancer Clinic Redesign: Opportunities for Resource Optimization

Author

Fung-Kee-Fung, Michael, primary, Ozer, Rachel S., additional, Davies, Bill, additional, Pick, Stephanie, additional, Duke, Kate, additional, Stewart, David J., additional, Reaume, M. Neil, additional, Ward, Marcus, additional, Balchin, Katelyn, additional, MacRae, Robert M., additional, Renaud, Julie, additional, Garvin, Dennis, additional, Madore, Suzanne, additional, and Pantarotto, Jason R., additional

Published
2021
Full Text
View/download PDF

26. 130: Radiation Oncologist Consultations Prior to Radical Prostatectomy in Ontario: Disparities and Implications for Health Human Resource Planning

Author

Corkum, Mark, primary, Loblaw, Andrew, additional, Morton, Gerard, additional, Louie, Alexander, additional, Glicksman, Rachel, additional, Chin, Joseph, additional, Kulkarni, Girish, additional, Dinniwell, Robert, additional, Fisher, Barbara, additional, Saskin, Refik, additional, Pantarotto, Jason, additional, Warner, Andrew, additional, and Rodrigues, George, additional

Published
2021
Full Text
View/download PDF

33. Radiation oncologist consultations prior to prostatectomy in Ontario, Canada: Disparities and opportunities.

Author

Corkum, Mark T, primary, Loblaw, Andrew, additional, Morton, Gerard, additional, Louie, Alexander V, additional, Glicksman, Rachel, additional, Chin, Joseph, additional, Kulkarni, Girish S., additional, Dinniwell, Robert E, additional, Fisher, Barbara Jean, additional, Saskin, Refik, additional, Pantarotto, Jason, additional, Warner, Andrew, additional, and Rodrigues, George, additional

Published
2021
Full Text
View/download PDF

39. A Phase II Multi-institutional Clinical Trial Assessing Fractionated Simultaneous In-Field Boost Radiotherapy for Brain Oligometastases

Author

Rodrigues, George, primary, Yartsev, Slav, additional, Roberge, David, additional, MacRae, Robert, additional, Roa, Wilson H, additional, Panet-Raymond, Valérie, additional, Masucci, Giuseppina Laura, additional, Yaremko, Brian P, additional, D'Souza, David, additional, Palma, David, additional, Sexton, Tracy, additional, Yu, Edward, additional, Pantarotto, Jason, additional, Ahmad, Belal, additional, Fisher, Barbara, additional, Dar, A. Rashid, additional, Lambert, Carole, additional, Pond, Gregory, additional, Tay, Keng Yeow, additional, and Bauman, Glenn, additional

Published
2019
Full Text
View/download PDF

43. Feasibility, detectability and clinical experience with platinum fiducial seeds for MRI/CT fusion and real-time tumor tracking during CyberKnife

Author

Vimoj J, Nair, Janos, Szanto, Eric, Vandervoort, Elizabeth, Henderson, Leonard, Avruch, Shawn, Malone, and Pantarotto, Jason R

Subjects
Physics Investigation
Abstract

The purpose of this study is to review our experience with platinum fiducials in terms of feasibility of placement and detectability by both MRI and orthogonal x-ray images used in robotic SABR.Materials and Methods: 29 consecutive SABR patients (30 tumors) treated using fiducial tracking between January 2011 and February 2012 were reviewed. A total of 108 fiducials implanted in or around various tumor sites were identified. The pixel value contrast (PVC) of fiducials seen on MRI mages and treatment unit x-ray images of patients and phantoms were analysed.Migration rates were similar for PS versus GS and GC (6.2%). No difference was noted between the mean PVC in cirrhotic versus non-cirrhotic liver (60.4 vs. 47.9; p = 0.074). MRI sequences for tumors in the liver and other organs revealed a mean PVC for platinum superior to that of gold (p0.001). No PVC difference was seen between gold and platinum on analysis of the treatment unit x-rays.Platinum seeds provide a superior detectability in comparison to gold seeds or coils on MRI images and are detected equally well by an image guidance system using orthogonal x-rays, making them a better choice for fiducial-based CT-MRI registration.

Published
2018

44. Validating impact of pretreatment tumor growth rate on outcome of early‐stage lung cancer treated with stereotactic body radiation therapy.

Author

Atallah, Soha, Le, Lisa W., Bezjak, Andrea, MacRae, Robert, Hope, Andrew J., and Pantarotto, Jason

Subjects
LUNG cancer prognosis, CANCER patients, COMPUTED tomography, LUNG cancer, MEDICAL records, RADIOSURGERY, SEX distribution, TUMOR classification, PREDICTION models, TREATMENT effectiveness, RETROSPECTIVE studies, PREOPERATIVE period, DESCRIPTIVE statistics, ACQUISITION of data methodology, LOG-rank test
Abstract

Background: To assess correlation of pretreatment specific growth rate (SGR) value of 0.43 × 10‐2 with overall and failure‐free survival of patients with early‐stage non‐small cell lung cancer (NSCLC) treated with stereotactic body radiation therapy (SBRT). Methods: A retrospective chart review of 160 patients with pathologically confirmed stage I NSCLC treated with SBRT between June 2010 and December 2012 in a large, tertiary cancer institute was undertaken. Both diagnostic and archived planning CT were uploaded to the treatment planning system to determine tumor volume at diagnosis (GTV1) and planning time (GTV2). The time (t) between both CTs was recorded. SGR was calculated using GTV1, GTV2, and t. The median SGR (0.43 × 10‐2) from our previous data was used to group patients into low and high SGR cohorts. Log‐rank test was used to compare overall (OS) and failure‐free survivals (FFS) of SGR groups. Results: The median time interval between diagnostic and planning CT scans was 87 days. The median OS was 38 and 66 months for high and low SGR cohorts, respectively (P = 0.03). The median FFS was 27 and 55 months for high and low SGR cohorts, respectively (P = 0.005). High SGR (P < 0.05), male gender (P = <0.01), and GTV2 (P = <0.05) were associated with poorer FFS. Conclusions: High SGR was associated with poorer outcome in patients with early‐stage NSCLC treated with SBRT. SGR can be used in conjunction with other well‐known predictive factors to formulate a practical predictive model to identify subgroups of the patient at higher risk of recurrence after SBRT. [ABSTRACT FROM AUTHOR]

Published
2021
Full Text
View/download PDF

45. Concurrent once-daily versus twice-daily chemoradiotherapy in patients with limited-stage small-cell lung cancer (CONVERT) : an open-label, phase 3, randomised, superiority trial

Author

Faivre-Finn, Corinne, Snee, Michael, Ashcroft, Linda, Appel, Wiebke, Barlesi, Fabrice, Bhatnagar, Adityanarayan, Bezjak, Andrea, Cardenal, Felipe, Fournel, Pierre, Harden, Susan, Le Pechoux, Cecile, McMenemin, Rhona, Mohammed, Nazia, O'Brien, Mary, Pantarotto, Jason, Surmont, Veerle, van Meerbeeck, Jan, Woll, Lorigan, Paul, Blackhall, Fiona, and Woll, Penella J.

Subjects
Human medicine
Abstract

Background Concurrent chemoradiotherapy is the standard of care in limited-stage small-cell lung cancer, but the optimal radiotherapy schedule and dose remains controversial. The aim of this study was to establish a standard chemoradiotherapy treatment regimen in limited-stage small-cell lung cancer. Methods The CONVERT trial was an open-label, phase 3, randomised superiority trial. We enrolled adult patients (aged ≥18 years) who had cytologically or histologically confirmed limited-stage small-cell lung cancer, Eastern Cooperative Oncology Group performance status of 02, and adequate pulmonary function. Patients were recruited from 73 centres in eight countries. Patients were randomly assigned to receive either 45 Gy radiotherapy in 30 twice-daily fractions of 1·5 Gy over 19 days, or 66 Gy in 33 once-daily fractions of 2 Gy over 45 days, starting on day 22 after commencing cisplatinetoposide chemotherapy (given as four to six cycles every 3 weeks in both groups). The allocation method used was minimisation with a random element, stratified by institution, planned number of chemotherapy cycles, and performance status. Treatment group assignments were not masked. The primary endpoint was overall survival, defined as time from randomisation until death from any cause, analysed by modified intention-to-treat. A 12% higher overall survival at 2 years in the once-daily group versus the twice-daily group was considered to be clinically significant to show superiority of the once-daily regimen. The study is registered with ClinicalTrials.gov (NCT00433563) and is currently in follow-up. Findings Between April 7, 2008, and Nov 29, 2013, 547 patients were enrolled and randomly assigned to receive twice-daily concurrent chemoradiotherapy (274 patients) or once-daily concurrent chemoradiotherapy (273 patients). Four patients (one in the twice-daily group and three in the once-daily group) did not return their case report forms and were lost to follow-up; these patients were not included in our analyses. At a median follow-up of 45 months (IQR 3558), median overall survival was 30 months (95% CI 2434) in the twice-daily group versus 25 months (2131) in the once-daily group (hazard ratio for death in the once daily group 1·18 [95% CI 0·951·45]; p=0·14). 2-year overall survival was 56% (95% CI 5062) in the twice-daily group and 51% (4557) in the once-daily group (absolute difference between the treatment groups 5·3% [95% CI −3·2% to 13·7%]). The most common grade 34 adverse event in patients evaluated for chemotherapy toxicity was neutropenia (197 [74%] of 266 patients in the twice-daily group vs 170 [65%] of 263 in the once-daily group). Most toxicities were similar between the groups, except there was significantly more grade 4 neutropenia with twice-daily radiotherapy (129 [49%] vs 101 [38%]; p=0·05). In patients assessed for radiotherapy toxicity, was no difference in grade 34 oesophagitis between the groups (47 [19%] of 254 patients in the twice-daily group vs 47 [19%] of 246 in the once-daily group; p=0·85) and grade 34 radiation pneumonitis (4 [3%] of 254 vs 4 [2%] of 246; p=0·70). 11 patients died from treatment-related causes (three in the twice-daily group and eight in the once-daily group). Interpretation Survival outcomes did not differ between twice-daily and once-daily concurrent chemoradiotherapy in patients with limited-stage small-cell lung cancer, and toxicity was similar and lower than expected with both regimens. Since the trial was designed to show superiority of once-daily radiotherapy and was not powered to show equivalence, the implication is that twice-daily radiotherapy should continue to be considered the standard of care in this setting.

Published
2017

49. Directly Improving the Quality of Radiation Treatment Through Peer Review: A Cross-sectional Analysis of Cancer Centers Across a Provincial Cancer Program

Author

Rouette, Julie, primary, Gutierrez, Eric, additional, O'Donnell, Jennifer, additional, Reddeman, Lindsay, additional, Hart, Margaret, additional, Foxcroft, Sophie, additional, Mitera, Gunita, additional, Warde, Padraig, additional, Brundage, Michael D., additional, Czarnota, Gregory, additional, El-Mallah, Medhat, additional, Falkson, Conrad, additional, Liu, Fei-Fei, additional, Gulavita, Sunil, additional, McMillan, William, additional, Pantarotto, Jason, additional, Rachakonda, Ramana, additional, Read, Nancy, additional, Schneider, Ken, additional, Shehata, Sarwat, additional, Stevens, Christiaan, additional, Tsao, Jonathan, additional, Waldron, John, additional, Wells, Woodrow, additional, Wright, Jim, additional, Sharpe, Michael, additional, Lockhart, Elizabeth, additional, Brundage, Michael, additional, Caissie, Amanda, additional, Hollenhorst, Helmut, additional, Wilson, Lianne, additional, Parliament, Matthew, additional, Milosevic, Michael, additional, Halperin, Ross, additional, Ebacher, Annie, additional, and McGowan, Thomas, additional

Published
2017
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results